Search results with tag "Recist 1"
KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or in ...
www.mirati.comSep 18, 2021 · ORR (RECIST 1.1) Secondary: Safety. Presented at the European Society for Medical Oncology (ESMO) Congress, 18 September 2021. KRYSTAL-1: Adagrasib (MRTX849) KRAS. G12C. Inhibitor ± Cetuximab in CRC. 600 mg BID n=2 (CRC) Expansion. 5. Demographics and Baseline Characteristics. Adagrasib Monotherapy. a (n=46) Adagrasib + Cetuximab. b
Oncology Trials 101 - The Basics and Then Some - PharmaSUG
www.pharmasug.orgIn January 2009, a consortium published RECIST 1.1 as the first formal revision. The intent was to address some of the original’s shortcomings, as well as to reflect realities of current clinical practices and prioritizes Target Lesions. Positive results for blood cancers such as leukemia involve measuring the reduction of and
Response assessment criteria for brain metastases ...
imaging.cancer.govwith RECIST 1.1. Patients with non-measurable disease can still be included in trials where response is not the primary endpoint (eg, in trials with progression-free survival, overall survival, or other primary endpoints). For studies in which CNS objective response is the